In order to promote the clinical application of c-Met targeted drugs for DSTs, it is necessary to explore the mechanism of c-Met action in DSTs so as to optimize the anti-tumor activity and treatment regimens of c-Met drugs. The gene discussed is MET; the disease is neoplasm.